BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32585842)

  • 1. A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.
    Marverti G; Gozzi G; Maretti E; Lauriola A; Severi L; Sacchetti F; Losi L; Pacifico S; Ferrari S; Ponterini G; Leo E; Costi MP; D'Arca D
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
    Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-Promoted Release of a Novel Anti-Tumour Peptide by "Stealth" Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells.
    Sacchetti F; Marverti G; D'Arca D; Severi L; Maretti E; Iannuccelli V; Pacifico S; Ponterini G; Costi MP; Leo E
    Pharm Res; 2018 Sep; 35(11):206. PubMed ID: 30209680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
    Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
    Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
    Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
    Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones?
    Sacchetti F; D'Arca D; Genovese F; Pacifico S; Maretti E; Hanuskova M; Iannuccelli V; Costi MP; Leo E
    Drug Dev Ind Pharm; 2017 Mar; 43(3):465-473. PubMed ID: 27885848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
    Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
    Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study.
    Fanciullino R; Giacometti S; Aubert C; Fina F; Martin PM; Piccerelle P; Ciccolini J
    Pharm Res; 2005 Dec; 22(12):2051-7. PubMed ID: 16222443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells.
    Shaw D; Berger FG; Spencer HT
    Hum Gene Ther; 2001 Jan; 12(1):51-9. PubMed ID: 11177542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomolecular study of human thymidylate synthase conformer-selective inhibitors: New chemotherapeutic approach.
    El-Mesallamy HO; El Magdoub HM; Chapman JM; Hamdy NM; Schaalan MF; Hammad LN; Berger SH
    PLoS One; 2018; 13(3):e0193810. PubMed ID: 29538414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
    Fanciullino R; Giacometti S; Mercier C; Aubert C; Blanquicett C; Piccerelle P; Ciccolini J
    Br J Cancer; 2007 Oct; 97(7):919-26. PubMed ID: 17848948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
    Di Gennaro E; Bruzzese F; Pepe S; Leone A; Delrio P; Subbarayan PR; Avallone A; Budillon A
    Cancer Biol Ther; 2009 May; 8(9):782-91. PubMed ID: 19270508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth.
    Pacifico S; Santucci M; Luciani R; Saxena P; Linciano P; Ponterini G; Lauriola A; D'Arca D; Marverti G; Guerrini R; Costi MP
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31561530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance in colon cancer.
    Gorlick R; Bertino JR
    Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
    Wang W; Marsh S; Cassidy J; McLeod HL
    Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
    Raymond E; Djelloul S; Buquet-Fagot C; Mester J; Gespach C
    Anticancer Drugs; 1996 Sep; 7(7):752-7. PubMed ID: 8949986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
    Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
    Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs in therapy of colorectal cancer: preclinical studies.
    Rustum YM; Cao S
    Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.